New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.